GleamWall
中文EN

SUPN Supernus, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1625297 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY16.3%
TTM net income YoY251.6%
TTM EPS YoY253.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin85.0%
Operating margin40.6%
Net margin32.8%
FCF margin2.3%
EBITDA margin41.1%

Returns

ROE—
ROA32.8%
ROIC (approx.)—
Asset turnover1.00x

Leverage & solvency

Liabilities / assets104.5%
Debt / equity—
Current ratio0.61x
Interest coverage32.82x

Cash quality & payout

Operating cash flow / net income0.21x
Accruals ratio25.8%
Payout ratio—
Capex / revenue4.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$356.00M$343.00M$317.00M$358.00M$314.00M$302.00M$266.00M$299.00M
Cost of revenue$51.00M$50.00M$40.00M$67.00M$83.00M$52.00M$44.00M$48.00M
Gross profit$305.00M$294.00M$277.00M$292.00M$230.00M$250.00M$221.00M$250.00M
R&D expense$5.00M$12.00M$16.00M$21.00M$33.00M$21.00M$22.00M$31.00M
SG&A expense$119.00M$122.00M$124.00M$189.00M$154.00M$158.00M$133.00M$175.00M
Operating income$180.00M$160.00M$137.00M$81.00M$43.00M$72.00M$66.00M$46.00M
Interest expense$2.00M$2.00M$7.00M$6.00M$12.00M$15.00M$12.00M$13.00M
Pretax income$182.00M$160.00M$115.00M$81.00M$37.00M$62.00M$59.00M$38.00M
Income tax$45.00M$38.00M$26.00M-$21.00M-$5.00M$44.00M$11.00M$17.00M
Net income$137.00M$122.00M$89.00M$102.00M$42.00M$18.00M$47.00M$21.00M
EBITDA$181.00M$162.00M$139.00M$83.00M$46.00M$72.00M$69.00M$64.00M
EPS (basic)1.161.020.71—0.340.150.38—
EPS (diluted)1.120.980.69—0.330.140.38—
Weighted avg. shares (diluted)122.00M124.00M129.00M—129.00M126.00M125.00M—
Balance sheet
Cash & equivalents$305.00M$222.00M$175.00M$195.00M$445.00M$510.00M$372.00M$319.00M
Short-term investments———$0$0$0$1.00M$1.00M
Receivables$273.00M$271.00M$273.00M$253.00M$259.00M$240.00M$243.00M$254.00M
Inventory$149.00M$150.00M$152.00M$153.00M$155.00M$149.00M$163.00M$167.00M
Current assets$800.00M$725.00M$667.00M$652.00M$922.00M$951.00M$883.00M$827.00M
PP&E, net$175.00M$162.00M$157.00M$144.00M$124.00M$117.00M$104.00M$100.00M
Goodwill———$2.00M———$2.00M
Total assets$1.33B$1.23B$1.20B$1.20B$1.42B$1.45B$1.38B$1.32B
Current liabilities$1.30B$868.00M$779.00M$914.00M$965.00M$1.06B$1.00B$924.00M
Short-term debt$488.00M$0$0$29.00M$18.00M$18.00M$18.00M$18.00M
Long-term debt$0$487.00M$486.00M$290.00M$304.00M$308.00M$311.00M$315.00M
Total debt$488.00M$487.00M$486.00M$319.00M$322.00M$326.00M$329.00M$333.00M
Total liabilities$1.39B$1.44B$1.34B$1.30B$1.62B$1.71B$1.66B$1.65B
Shareholders' equity-$60.00M-$208.00M-$144.00M-$98.00M-$207.00M-$257.00M-$285.00M-$337.00M
Net debt$183.00M$265.00M$311.00M$124.00M-$123.00M-$184.00M-$43.00M$14.00M
Cash flow statement
Operating cash flow$97.00M$229.00M-$9.00M-$221.00M-$39.00M$158.00M$75.00M-$17.00M
Capital expenditure$14.00M$7.00M$20.00M$24.00M$20.00M$17.00M$5.00M$16.00M
Free cash flow$83.00M$222.00M-$29.00M-$245.00M-$59.00M$141.00M$70.00M-$33.00M
Investing cash flow-$14.00M-$8.00M-$19.00M-$24.00M-$20.00M-$17.00M-$5.00M$8.00M
Financing cash flow$0-$173.00M$7.00M-$5.00M-$3.00M-$5.00M-$17.00M$40.00M
Depreciation & amortization$1.00M$2.00M$2.00M$2.00M$3.00M$0$3.00M$18.00M
Stock-based compensation$8.00M$11.00M$9.00M$5.00M$6.00M$8.00M$6.00M$6.00M
Share buybacks$0$176.00M$125.00M$0$0$0$11.00M$50.00M

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.